RESUMEN

Mutations in the ATG genes have been related to impair autophagic function, contributing to the sporadic onset of Parkinsons Disease (PD). However, scarce studies have been performed about ins/del within the regulatory domains of the autophagy genes in sporadic PD patients. This study was aimed to found ins/del within part of the crucial core autophagy promotor gene region of the ATG16L1 in a groups of sporadic PD patients. After developing a genetic marker to find ins/del using fragment size analysis, a rare mutation by insertion (0.45%) was reported in the patients. This mutation was characterized by sequencing. No others ins/del were found. As a results, the frequency of this insertion should be considered as a rare genetic variant. An in silico analysis also highlighting the usefulness of a search GDV which revealed multiples ins/del within ATG16L1 promoter. Furthermore, these genetic insertions could be found in patients with sporadic PD in the ATG161L promoter gene. When a breakpoint as deletions, insertions or tandem duplication are located within a functional gene interruption of the gene and a loss of function was expected but removing or altering in the regulatory sequence can influence the expression or the regulation of a nearby gene which may impair healthy due to dosage effects in sporadic diseases.

Asunto(s)

Predisposición Genética a la Enfermedad , Enfermedad de Parkinson , Humanos , Estudios de Casos y Controles , Variación Genética , Enfermedad de Parkinson/genética , Regiones Promotoras Genéticas/genética

RESUMEN

The pandemic caused by the new SARS-CoV2 coronavirus has led to an effort to find treatments that are effective against this disease that the World Health Organization calls COVID-19. In severe cases of COVID-19, there is an increase in cytokines, among which IL-6 seems to play an important role. A search has been performed for studies using IL-6 blocking drugs (tocilizumab, siltuximab, and sarilumab) in PubMed, Web of Science, and Scopus. Also, a search of ongoing trials registered at clinicaltrials.gov was performed. We found very little published clinical experience with these drugs, consisting mainly of case reports or case series with few patients. The results of clinical trials are necessary to clarify the role of these drugs in patients with COVID-19.

Asunto(s)

Anticuerpos Monoclonales Humanizados/farmacología , Anticuerpos Monoclonales/farmacología , Antivirales/farmacología , Betacoronavirus/efectos de los fármacos , Interleucina-6/antagonistas & inhibidores , Betacoronavirus/inmunología , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/inmunología , Humanos , Interleucina-6/inmunología , Pandemias/prevención & control , Neumonía Viral/diagnóstico , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/inmunología , SARS-CoV-2

RESUMEN

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been associated with Parkinson's disease, and its inhibition opens potential new therapeutic options. Among the drug inhibitors of both wild-type and mutant LRRK2 forms is the 2-arylmethyloxy-5-subtitutent-N-arylbenzamide GSK257815A. Using the well-established dopaminergic cell culture model SH-SY5Y, we have investigated the effects of GSK2578215A on crucial neurodegenerative features such as mitochondrial dynamics and autophagy. GSK2578215A induces mitochondrial fragmentation of an early step preceding autophagy. This increase in autophagosome results from inhibition of fusion rather than increases in synthesis. The observed effects were shared with LRRK2-IN-1, a well-described, structurally distinct kinase inhibitor compound or when knocking down LRRK2 expression using siRNA. Studies using the drug mitochondrial division inhibitor 1 indicated that translocation of the dynamin-related protein-1 has a relevant role in this process. In addition, autophagic inhibitors revealed the participation of autophagy as a cytoprotective response by removing damaged mitochondria. GSK2578215A induced oxidative stress as evidenced by the accumulation of 4-hydroxy-2-nonenal in SH-SY5Y cells. The mitochondrial-targeted reactive oxygen species scavenger MitoQ positioned these species as second messengers between mitochondrial morphologic alterations and autophagy. Altogether, our results demonstrated the relevance of LRRK2 in mitochondrial-activated pathways mediating in autophagy and cell fate, crucial features in neurodegenerative diseases.

Asunto(s)

Aminopiridinas/toxicidad , Autofagia/efectos de los fármacos , Benzamidas/toxicidad , Mitocondrias/metabolismo , Dinámicas Mitocondriales/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Aldehídos/metabolismo , Benzodiazepinonas/farmacología , Línea Celular Tumoral , Dinaminas , GTP Fosfohidrolasas/metabolismo , Humanos , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina , Proteínas Asociadas a Microtúbulos/metabolismo , Proteínas Mitocondriales/metabolismo , Compuestos Organofosforados/farmacología , Estrés Oxidativo/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/genética , Proteínas Serina-Treonina Quinasas/metabolismo , Pirimidinas/farmacología , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Transducción de Señal/efectos de los fármacos , Ubiquinona/análogos & derivados , Ubiquinona/farmacología

RESUMEN

Retinal pigment epithelium has a crucial role in the physiology and pathophysiology of the retina due to its location and metabolism. Oxidative damage has been demonstrated as a pathogenic mechanism in several retinal diseases, and reactive oxygen species are certainly important by-products of ethanol (EtOH) metabolism. Autophagy has been shown to exert a protective effect in different cellular and animal models. Thus, in our model, EtOH treatment increases autophagy flux, in a concentration-dependent manner. Mitochondrial morphology seems to be clearly altered under EtOH exposure, leading to an apparent increase in mitochondrial fission. An increase in 2',7'-dichlorofluorescein fluorescence and accumulation of lipid peroxidation products, such as 4-hydroxy-nonenal (4-HNE), among others were confirmed. The characterization of these structures confirmed their nature as aggresomes. Hence, autophagy seems to have a cytoprotective role in ARPE-19 cells under EtOH damage, by degrading fragmented mitochondria and 4-HNE aggresomes. Herein, we describe the central implication of autophagy in human retinal pigment epithelial cells upon oxidative stress induced by EtOH, with possible implications for other conditions and diseases.

Asunto(s)

Aldehídos/efectos adversos , Autofagia/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Etanol/efectos adversos , Mitocondrias/metabolismo , Enfermedades de la Retina/fisiopatología , Epitelio Pigmentado de la Retina/citología , Apoptosis/efectos de los fármacos , Línea Celular , Células Epiteliales/citología , Células Epiteliales/metabolismo , Humanos , Mitocondrias/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Enfermedades de la Retina/etiología , Enfermedades de la Retina/metabolismo , Epitelio Pigmentado de la Retina/efectos de los fármacos , Epitelio Pigmentado de la Retina/metabolismo

RESUMEN

INTRODUCTION: Stroke leads the list of causes of disability in adults and represents the second leading cause of death worldwide. Knowledge about the pathophysiology of ischemic stroke has improved substantially over the past 25 years, and, as a result of this, new therapeutic strategies have been developed with two main aims: restoration of cerebral flow and the minimization of the deleterious effects of ischemia on neurons. Although so far there are no drugs approved for the neuroprotection therapy in stroke, there are some compounds with promising results. DEVELOPMENT: This paper makes a critical review of several studies on the preclinical stroke neuroprotection with drugs aimed to protect the brain tissue adjacent to the damaged central area or ischemic penumbra zone until either the physiological mechanisms or the treatment stop the ischemic insult. We expose the potential neuroprotective properties of these treatments mainly based on inhibiting excitotoxicity processes mediated by gamma-aminobutyric acid receptors, glutamate release and interacting with ion channels such as calcium and sodium. We focus on drugs which have shown to be capable of modulating intracellular degenerative pathways in mitochondria mediated apoptosis or the expression of apoptotic proteins in experimental models. CONCLUSION: It is very likely that the neuroprotective effects require a poly-drug therapy that combines different mechanisms of action.

Asunto(s)

Fármacos Neuroprotectores , Accidente Cerebrovascular/tratamiento farmacológico , Animales , Bloqueadores de los Canales de Calcio/farmacología , Bloqueadores de los Canales de Calcio/uso terapéutico , Quimioterapia Combinada , Antagonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Fibrinolíticos/farmacología , Fibrinolíticos/uso terapéutico , Humanos , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Accidente Cerebrovascular/patología , Accidente Cerebrovascular/fisiopatología , Terapia Trombolítica

RESUMEN

INTRODUCTION: During the last decade, the neuroprotective effects of minocycline have been a matter of an intense debate. A broad amount of contradictory studies can be found in the scientific literature, going from neuroprotection to the exacerbation of toxicity in diverse experimental models. Such differences could be the result of minocycline acting on multiple pharmacological targets. DEVELOPMENT: In the present review we will go over these pharmacological targets and the effects derived from their modulation by minocycline. Among others, its antioxidant activity derived from its chemical structure or its modulator effect on several enzymes such as nitric oxide synthase will be reviewed. Furthermore, the effects of minocycline on the intracellular pathways implicated in neurodegenerative processes including apoptosis stages, activation decision and execution will be addressed. CONCLUSIONS: All the mechanisms described herein have not escaped to a scientific community needed of new therapeutic drugs for the treatment of neurodegenerative conditions. However, the sparse clinical trials carried out so far are mainly aimed at assessing its tolerability and safety or are still in progress. We believe that more studies, both clinical and pre-clinical, should be carried out in order to ascertain the therapeutic window and the neurodegenerative disorders in which minocycline could be useful.

Asunto(s)

Minociclina/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Humanos , Minociclina/farmacología , Enfermedades Neurodegenerativas/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología

RESUMEN

In this review we explore and integrate the knowledge of the plausible pharmacological targets that could explain the new application for the well known semi-synthetic, tetracycline-derivate minocycline as a cytoprotective drug. In doing so, we will analyze the possible mechanisms to elucidate the potential cytoprotective properties of minocycline. We address its anti-oxidant action ranging from its structure to its capacity to modulate the expression of oxidant-related enzymes such as nitric oxide synthase. The pharmacological targets responsible for its anti-inflammatory effects are surveyed. The effects of this antibiotic are making its marks on intracellular pathways related to neurodegenerative processes such as mitochondrially-mediated apoptosis, including minocycline-modulated effects on the expression of apoptotic proteins. Finally, we will explore the effects of minocycline on metalloproteinases, enzymes implicated in the modulation of cerebrovascular post-ischemic oxidative reperfusion injury, and new targets. In conclusion, we shed new light on the shadowy controversy of minocycline's potential cytoprotective mechanisms and targets of action.

Asunto(s)

Antibacterianos/farmacología , Antioxidantes/farmacología , Citoprotección , Minociclina/farmacología , Apoptosis/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Humanos , Metaloproteasas/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Enfermedades Neurodegenerativas/tratamiento farmacológico , Óxido Nítrico Sintasa/efectos de los fármacos

RESUMEN

Malonate, an inhibitor of mitochondrial complex II, is a widely used toxin to study neurodegeneration in Huntington's disease and ischemic stroke. We have shown previously that malonate increased reactive oxygen species (ROS) production in human SH-SY5Y neuroblastoma cells, leading to oxidative stress, cytochrome c release, and apoptotic cell death. Expression of a green fluorescent protein-Bax fusion protein in SH-SY5Y neuroblastoma cells demonstrated a Bax redistribution from the cytosol to mitochondria after 12 to 24 h of malonate treatment that coincided with mitochondrial potential collapse and chromatin condensation. Inhibition of Bax translocation using furosemide, as well as Bax gene deletion, afforded significant protection against malonate-induced apoptosis. Further experiments revealed that malonate induced a prominent increase in the level of activated p38 mitogen-activated protein (MAP) kinase and that treatment with the p38 MAP kinase inhibitor SKF86002 potently blocked malonate-induced Bax translocation and apoptosis. Treatment with vitamin E diminished ROS production, reduced the activation status of p38 MAP kinase, inhibited Bax translocation, and protected against malonate-induced apoptosis. Our data suggest that malonate-induced ROS production and subsequent p38 MAP kinase activation mediates the activation of the pro-apoptotic Bax protein to induce mitochondrial membrane permeabilization and neuronal apoptosis.

Asunto(s)

Apoptosis/efectos de los fármacos , Citocromos c/metabolismo , Malonatos/farmacología , Mitocondrias/efectos de los fármacos , Especies Reactivas de Oxígeno , Proteína X Asociada a bcl-2/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/fisiología , Animales , Células Cultivadas , Malondialdehído/análisis , Mitocondrias/metabolismo , Transporte de Proteínas/efectos de los fármacos , Ratas

RESUMEN

Parkinson disease (PD) is the second-most common age-related neurodegenerative disease and is characterized by the selective destruction of dopaminergic neurons. Increasing evidence indicates that oxidative stress plays a crucial role in the pathogenesis of idiopathic PD. Anti-oxidant agents including catalase, manganese porphyrin and pyruvate confer cytoprotection to different cell cultures when challenged with 6-hydroxydopamine (6-OHDA). Herein we used rat cerebellar granular cell cultures to ascertain the plausible cellular pathways involved in pyruvate-induced cytoprotection against 0.1 mM 6-OHDA. Pyruvate provided cytoprotection in a concentration-dependent manner (2-10 mM). Consistent with its well-established anti-oxidant capacity, pyruvate (10 mM) prevented 6-OHDA-induced lipid peroxidation by blocking the rise in intracellular peroxides and maintaining the intracellular reduced glutathione (GSH) levels. Further experiments revealed that pyruvate increased Akt, but not extracellular signal-regulated kinase phosphorylation. Moreover, phosphatidylinositol 3-kinase (PI3K) inhibitors attenuated pyruvate-induced cytoprotection indicating that PI3K-mediated Akt activation is necessary for pyruvate to induce cytoprotection. On the other hand, pyruvate also up-regulated glutathione peroxidase mRNA levels, but not those of the anti-oxidant enzymes superoxide dismutase-1 and -2, catalase or the anti-apoptotic oncogenes Bcl-2 or Bcl-xL. In summary, our results strongly suggest that pyruvate, besides the anti-oxidant properties related to its structure, exerts cytoprotective actions by activating different anti-apoptotic routes that include gene regulation and Akt pathway activation.

Asunto(s)

Corteza Cerebelosa/efectos de los fármacos , Degeneración Nerviosa/tratamiento farmacológico , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Proteínas Proto-Oncogénicas c-akt/efectos de los fármacos , Ácido Pirúvico/farmacología , Animales , Animales Recién Nacidos , Antioxidantes/metabolismo , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Células Cultivadas , Corteza Cerebelosa/metabolismo , Corteza Cerebelosa/fisiopatología , Citoprotección/efectos de los fármacos , Citoprotección/fisiología , Relación Dosis-Respuesta a Droga , Quinasas MAP Reguladas por Señal Extracelular/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Glutatión Peroxidasa/efectos de los fármacos , Glutatión Peroxidasa/genética , Glutatión Peroxidasa/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/fisiología , Degeneración Nerviosa/fisiopatología , Degeneración Nerviosa/prevención & control , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/metabolismo , Neurotoxinas/antagonistas & inhibidores , Neurotoxinas/toxicidad , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Oxidopamina/antagonistas & inhibidores , Oxidopamina/toxicidad , Fosfatidilinositol 3-Quinasas/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3 , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ácido Pirúvico/metabolismo , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Ratas , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiología

RESUMEN

Experimental and clinical studies support the view that the semisynthetic tetracycline minocycline exhibits neuroprotective roles in several models of neurodegenerative diseases, including ischemia, Huntington, Parkinson diseases, and amyotrophic lateral sclerosis. However, recent evidence indicates that minocycline does not always present beneficial actions. For instance, in an in vivo model of Huntington's disease, it fails to afford protection after malonate intrastriatal injection. Moreover, it reverses the neuroprotective effect of creatine in nigrostriatal dopaminergic neurons. This apparent contradiction prompted us to analyze the effect of this antibiotic on malonate-induced cell death. We show that, in rat cerebellar granular cells, the succinate dehydrogenase inhibitor malonate induces cell death in a concentration-dependent manner. By using DFCA, monochlorobimane and 10-N-nonyl-Acridin Orange to measure, respectively, H2O2-derived oxidant species and reduced forms of GSH and cardiolipin, we observed that malonate induced reactive oxygen species (ROS) production to an extent that surpasses the antioxidant defense capacity of the cells, resulting in GSH depletion and cardiolipin oxidation. The pre-treatment for 4 h with minocycline (10-100 microM) did not present cytoprotective actions. Moreover, minocycline failed to block ROS production and to abrogate malonate-induced oxidation of GSH and cardiolipin. Additional experiments revealed that minocycline was also unsuccessful to prevent the mitochondrial swelling induced by malonate. Furthermore, malonate did not induce the expression of the iNOS, caspase-3, -8, and -9 genes which have been shown to be up-regulated in several models where minocycline resulted cytoprotective. In addition, malonate-induced down-regulation of the antiapoptotic gene Bcl-2 was not prevented by minocycline, controversially the mechanism previously proposed to explain minocycline protective action. These results suggest that the minocycline protection observed in several neurodegenerative disease models is selective, since it is absent from cultured cerebellar granular cells challenged with malonate.

Asunto(s)

Apoptosis/efectos de los fármacos , Malonatos/antagonistas & inhibidores , Minociclina/farmacología , Degeneración Nerviosa/tratamiento farmacológico , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Animales , Animales Recién Nacidos , Apoptosis/fisiología , Cardiolipinas/efectos de los fármacos , Cardiolipinas/metabolismo , Caspasas/efectos de los fármacos , Caspasas/metabolismo , Células Cultivadas , Corteza Cerebelosa/efectos de los fármacos , Corteza Cerebelosa/metabolismo , Corteza Cerebelosa/patología , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/toxicidad , Glutatión/metabolismo , Malonatos/toxicidad , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/prevención & control , Neuronas/metabolismo , Neuronas/patología , Neurotoxinas/antagonistas & inhibidores , Neurotoxinas/toxicidad , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Proteínas Proto-Oncogénicas c-bcl-2/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas , Especies Reactivas de Oxígeno/metabolismo , Succinato Deshidrogenasa/antagonistas & inhibidores , Succinato Deshidrogenasa/metabolismo

RESUMEN

The pathogenesis of non-glutamatergic, depolarization-induced cell death is still enigmatic. Recently, we have shown that veratridine induces apoptosis in chromaffin cells, and we have demonstrated protective effects of antioxidants in this system, suggesting a role for Na+ channels and oxidative stress in depolarization-induced cell death. We examined the possible contribution of p53, a transcription factor that has a major role in determining cell fate, and the mitochondrial apoptosis pathway in veratridine-induced cell death of cultured bovine chromaffin cells. Nuclear condensation and fragmentation were detected several hours after a 60-min exposure to 30 microM veratridine. Apoptosis was associated with a transitory increase in p53 protein levels. Veratridine induced transcription of the pro-apoptotic p53 target gene PUMA, but not of bax or pig3. Using transient transfection experiments, we found that wild-type p53, but not the mutant form p53-273H, was sufficient to induce cell death in the chromaffin cells, which was caspase-9 dependent. The down-regulation of either p53, by overexpressing p53-273H, or caspase-9 activity using a dominant-negative caspase-9 mutant protected chromaffin cells against veratridine-induced toxicity. Our data demonstrate the importance of p53 and the downstream activation of the mitochondrial apoptosis pathway in depolarization-induced apoptosis.

Asunto(s)

Apoptosis/fisiología , Células Cromafines/patología , Genes p53/fisiología , Proteínas Supresoras de Tumor/fisiología , Animales , Apoptosis/efectos de los fármacos , Bovinos , Células Cultivadas , Células Cromafines/efectos de los fármacos , Electroforesis en Gel de Poliacrilamida , Genes p53/efectos de los fármacos , Immunoblotting , Inmunohistoquímica , Transfección , Proteínas Supresoras de Tumor/efectos de los fármacos , Veratridina/toxicidad

RESUMEN

Minocycline, a semisynthetic derivative of tetracycline, displays beneficial activity in neuroprotective in models including, Parkinson disease, spinal cord injury, amyotrophic lateral sclerosis, Huntington disease and stroke. The mechanisms by which minocycline inhibits apoptosis remain poorly understood. In the present report we have investigated the effects of minocycline on mitochondria, due to their crucial role in apoptotic pathways. In mitochondria isolated suspensions, minocycline failed to block superoxide-induced swelling but was effective in blocking mitochondrial swelling induced by calcium. This latter effect might be mediated through dissipation of mitochondrial transmembrane potential and blockade of mitochondrial calcium uptake. Consistently, minocycline fails to protect SH-SY5Y cell cultures against reactive oxygen species-mediated cell death, including malonate and 6-hydroxydopamine treatments, but it is effective against staurosporine-induced cytotoxicity. The effects of this antibiotic on mitochondrial respiratory chain complex were also analyzed. Minocycline did not modify complex IV activity, and only at the higher concentration tested (100 microM) inhibited complex II/III activity. Other members of the minocycline antibiotic family like tetracycline failed to induce these mitochondrial effects.

Asunto(s)

Calcio/metabolismo , Potenciales de la Membrana/efectos de los fármacos , Minociclina/farmacología , Mitocondrias/efectos de los fármacos , Dilatación Mitocondrial/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Animales , Calcio/farmacología , Recuento de Células/métodos , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Inhibidores Enzimáticos/farmacología , Glutatión/metabolismo , Humanos , NADP/metabolismo , Neuroblastoma , Ratas , Ratas Sprague-Dawley , Espectrofotometría/métodos , Estaurosporina/farmacología , Sales de Tetrazolio , Tiazoles

RESUMEN

AIMS: In this review we analyse the role played by the serine proteases in the nervous system and we focus on the role they play in degenerative processes. DEVELOPMENT: These proteolytic enzymes, together with the caspases, play a vital role in the processes regulating cell functioning, both in the development stages and following the response to a harmful stimulus. This family of proteases includes the granzymes and thrombin (TR). The former, which are closely related to proteases I and II and cathepsin G, are situated in the cytoplasmic granules of the activated T lymphocytes, together with other proteins such as perforin or cytolysin. Granzymes A and B are linked to degenerative processes. These enter the target cells thanks to the action of perforin and once inside they are translocated to the nucleus. Granzyme A has been isolated and identified as the agent responsible for the immediate and complete retraction of neurites in different models. Its physiological substrates include fibronectin, type IV collagen and the proteoglycans. Granzyme B is characterised by its being a cysteine protease with substrates such as prointerleukin 1 beta, TR receptor and poly(ADP ribose) polymerase. The family of TR type proteases includes proteases such as TR itself, plasmin, kallikrein, urokinase plasminogen activator and tissue plasminogen activator. TR is considered to be an early modulator in damaged tissues which acts as an extracellular signal of death, leading to the activation of intracellular mechanisms that appear to be mediated by calcium. Serine protease activity is regulated by endogenous inhibitors, such as plasminogen activator inhibitor, protease nexin 1 and neuroserpin. CONCLUSIONS: Upsets in the protease inhibitor balance are crucial in the processes involved in the neuronal plasticity and death induced by ischemia in the brain and by excitotoxins.

Asunto(s)

Degeneración Nerviosa/enzimología , Neuronas/citología , Serina Endopeptidasas/fisiología , Animales , Isquemia Encefálica/enzimología , Isquemia Encefálica/patología , Muerte Celular/fisiología , Granzimas , Humanos , Glicoproteínas de Membrana/fisiología , Plasticidad Neuronal/fisiología , Neuronas/enzimología , Perforina , Proteínas Citotóxicas Formadoras de Poros , Serina Endopeptidasas/clasificación , Inhibidores de Serina Proteinasa/fisiología , Especificidad por Sustrato , Linfocitos T/enzimología , Trombina/fisiología , Activador de Tejido Plasminógeno/fisiología

RESUMEN

The tumor suppressor gene p53 is a potent transcriptional regulator for genes involved in many cellular activities including cell cycle arrest and apoptosis. In this study, we examined the role of p53 in neuronal death induced by the sodium channel modulator veratridine. We also analyzed the involvement of Ca2+, mitochondria and reactive oxygen species in p53 activation. Exposure of hippocampal neurons to veratridine (0.3-100 microM) resulted in a dose-dependent neuronal death, measured 24 h after treatment. p53-Like immunoreactivity, undetectable in neurons under control conditions, was observed in about 25% of neurons, 7 h after veratridine exposure. Treatments that modified the alkaloid-induced Ca2+ influx including tetrodotoxin or Ca2+ removal, prevented either veratridine-induced cell death or p53 immunoreactivity. Mitochondria were involved in veratridine-induced cell death, as the alkaloid collapsed inner transmembrane mitochondrial potential in a Ca2+ influx dependent manner. Treatments of neuronal cultures with the permeability transitory pore blockers cyclosporin A and bongkrekic acid prevented veratridine-induced p53 immunoreactivity and neuronal death, placing mitochondria upstream of veratridine-induced p53 immunoreactivity. Reactive oxygen species also participated in veratridine-induced neurotoxicity and p53 activation. Antisense knockdown of p53 resulted in a significant increase in neuronal survival after veratridine treatment. This protective effect was maintained on N-methyl-D-aspartate or ischemia-induced death but not on staurosporine cytotoxicity. These results together suggest that p53-expression is involved in veratridine-induced neuronal death and that p53 might be a link between toxic stimuli of different types and neuronal death.

Asunto(s)

Muerte Celular/fisiología , Ácido Egtácico/análogos & derivados , Células Piramidales/fisiología , Proteína p53 Supresora de Tumor/fisiología , Animales , Calcio/metabolismo , Catalasa/farmacología , Muerte Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Maleato de Dizocilpina/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Ácido Egtácico/farmacología , Electrofisiología , Embrión de Mamíferos , Inhibidores Enzimáticos/farmacología , Agonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Fluorometría , Depuradores de Radicales Libres/farmacología , Fura-2/metabolismo , Hipocampo/citología , Inmunohistoquímica , Potenciales de la Membrana/efectos de los fármacos , Metaloporfirinas/farmacología , Mitocondrias/efectos de los fármacos , N-Metilaspartato/farmacología , Oligonucleótidos Antisentido/farmacología , Oxígeno/metabolismo , Células Piramidales/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Canales de Sodio/efectos de los fármacos , Estaurosporina/farmacología , Superóxidos/metabolismo , Tetrodotoxina/farmacología , Factores de Tiempo , Proteína p53 Supresora de Tumor/metabolismo , Veratridina/farmacología , Vitamina E/farmacología

RESUMEN

The frequency, morbidity and complexity of neurodegenerative diseases (NDD) make them the greatest therapeutic challenge to Medicine today. These diseases are characterized by a decreased number of cells in certain neuronal populations, which is clinically reflected in the appearance of specific symptoms. In this study, we will centre our attention on the two fundamental lines of action that, from a pharmacological point of view, are available for the treatment of NDD. The first is aetiopathogenic, and is aimed at stopping cell death and promoting the recovery of cell populations. The second line is physiopathological and seeks to prevent, delay or palliate the appearance of the symptoms indicating an alteration in the levels of neurotransmitters, and its chief objective is to maintain them. Pharmacology has already provided neurologists with a wide range of tried and tested drugs, yet the results obtained in research laboratories in the last few years seem to indicate that the number of therapeutic possibilities are very likely to rise sharply in the future. Progress made in genomics and the better understanding of cellular biochemical cycles allow us to expect that this century will finally be that of the Neurosciences, and that Neurology, without losing its cognitive essence, will start to be considered to be a speciality that is as therapeutic as it is diagnostic.

Asunto(s)

Enfermedades Neurodegenerativas/fisiopatología , Adyuvantes Inmunológicos/metabolismo , Antiinflamatorios/uso terapéutico , Apoptosis/fisiología , Colesterol/metabolismo , Sustancias de Crecimiento/metabolismo , Hormonas/metabolismo , Humanos , Enfermedades Neurodegenerativas/tratamiento farmacológico , Enfermedades Neurodegenerativas/metabolismo , Enfermedades Neurodegenerativas/patología , Neurotransmisores/metabolismo

RESUMEN

Las enfermedades neurodegenerativas (END), por su frecuencia, morbilidad y complejidad, suponen actualmente el mayor reto terapéutico de la medicina. Estas enfermedades se caracterizan por una disminución en el número de células en determinadas poblaciones neuronales, lo que se refleja clínicamente por la aparición de sintomatologías específicas. En esta revisión nos centraremos en las dos líneas de actuación fundamentales que desde el punto de vista de la farmacología hay abiertas en el tratamiento de las END: la primera, etiopatogénica, con el objetivo de detener la muerte celular y fomentar la recuperación de las poblaciones celulares; la segunda línea, fisiopatológica, busca prevenir, retardar o paliar la aparición de la sintomatología propia de la alteración en los niveles de neurotransmisores, y que presenta como objetivo principal el mantenimiento de los mismos. La farmacología ha dotado ya a los neurólogos de un amplio arsenal de fármacos de probada eficacia; sin embargo, los resultados obtenidos en los laboratorios de investigación en los últimos años hacen muy probable que las posibilidades terapéuticas aumenten considerablemente en el futuro. Los avances de la genómica y la mejor comprensión de los ciclos bioquímicos celulares hacen esperar que este siglo sea, por fin, el de las neurociencias, y que la neurología, sin perder su esencia cognitiva, empiece a considerarse una especialidad tan terapéutica como diagnóstica (AU)

Asunto(s)

Humanos , Enfermedades Neurodegenerativas , Apoptosis , Antiinflamatorios , Colesterol , Adyuvantes Inmunológicos , Hormonas , Sustancias de Crecimiento , Neurotransmisores

RESUMEN

Activation of group I metabotropic glutamate receptors (mGlu1 or -5 receptors) is known to either enhance or attenuate excitotoxic neuronal death depending on the experimental conditions. We have examined the possibility that these receptors may switch between two different functional modes in regulating excitotoxicity. In mixed cultures of cortical cells, the selective mGlu1/5 agonist, 3,5-dihydroxyphenylglycine (DHPG), amplified neurodegeneration induced by a toxic pulse of NMDA. This effect was observed when DHPG was either combined with NMDA or transiently applied to the cultures prior to the NMDA pulse. However, two consecutive applications of DHPG consistently produced neuroprotection. Similar effects were observed with DHPG or quisqualate (a potent agonist of mGlu1/5 receptors) in pure cultures of cortical neurons virtually devoid of astrocytes. In cultures of hippocampal pyramidal neurons, however, only protective effects of DHPG were seen suggesting that, in these particular cultures, group I mGlu receptors were endogenously switched into a "neuroprotective mode". The characteristics of the activity-dependent switch from facilitation to inhibition were examined in mixed cultures of cortical cells. The switch in the response to DHPG was observed when the two applications of the drug were separated by an interval ranging from 1-45 min, but was lost when the interval was extended to 90 min. In addition, this phenomenon required the initial activation of mGlu5 receptors (as indicated by the use of subtype-selective antagonists) and was mediated by the activation of protein kinase C. We conclude that group I mGlu receptors are subjected to an activity-dependent switch in regulating excitotoxic neuronal death and, therefore, the recent "history" of these receptors is critical for the response to agonists or antagonists.

Asunto(s)

Inhibición Neural/fisiología , Neurotoxinas/metabolismo , Receptores de Glutamato Metabotrópico/fisiología , Animales , Células Cultivadas , Corteza Cerebral/citología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/fisiología , Activación Enzimática/fisiología , Agonistas de Aminoácidos Excitadores/envenenamiento , Antagonistas de Aminoácidos Excitadores/farmacología , Glicina/análogos & derivados , Glicina/farmacología , Ratones , N-Metilaspartato/envenenamiento , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/patología , Fármacos Neuroprotectores/farmacología , Proteína Quinasa C/metabolismo , Ácido Quiscuálico/farmacología , Receptor del Glutamato Metabotropico 5 , Resorcinoles/farmacología , Factores de Tiempo

RESUMEN

OBJECTIVE: This is a review of the part played by the cysteine proteases in different physiological and pathological processes. DEVELOPMENT: Apoptotic processes have a crucial function in control of the number of cells in multicellular organisms, both during development and throughout life. Alterations in these are closely related to different pathological processes, from cancer (with fewer apoptotic processes) to the degenerative disorders in which apoptosis is increased. Although the stimuli which may induce apoptosis are very varied, the apoptotic phenotypes are similar. Different metabolic routes are involved in apoptosis and in these changes, both in transcription and postranscription. The latter form the basis of this paper. We review the role of the cysteine protease family, in which the caspases and calpains are the best representatives, which have been related to different degenerative models. In this review we describe the stimuli and cascades of intracellular signalling which occur on activation. CONCLUSION: These proteases are involved in many situations involving the development and maintenance of the number of cells in the tissues, both physiological and pathological. They may be considered to be possible therapeutic targets in neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease and Huntington's chorea.

Asunto(s)

Cisteína Endopeptidasas/metabolismo , Enfermedades Neurodegenerativas/enzimología , Apoptosis/fisiología , Caspasas/clasificación , Caspasas/metabolismo , Humanos , Proteínas de la Membrana/metabolismo , Factor de Crecimiento Nervioso/fisiología , Receptores del Factor de Necrosis Tumoral/metabolismo , Receptor fas/metabolismo

RESUMEN

The molecular mechanisms involved in veratridine-induced chromaffin cell death have been explored. We have found that exposure to veratridine (30 microM, 1 h) produces a delayed cellular death that reaches 55% of the cells 24 h after veratridine exposure. This death has the features of apoptosis as DNA fragmentation can be observed. Calcium ions play an important role in veratridine-induced chromaffin cell death because the cell permeant Ca(2+) chelator BAPTA-AM and extracellular Ca(2+) removal completely prevented veratridine-induced toxicity. Following veratridine treatment, there is a decrease in mitochondrial function and an increase in superoxide anion production. Veratridine-induced increase in superoxide production was blocked by tetrodotoxin (TTX; 10 microM), extracellular Ca(2+) removal and the mitochondrial permeability transition pore blocker cyclosporine A (10 microM). Veratridine-induced death was prevented by different antioxidant treatments including catalase (100 IU ml(-1)), N-acetyl cysteine (100 microM), allopurinol (100 microM) or vitamin E (50 microM). Veratridine-induced DNA fragmentation was prevented by TTX (10 microM). Veratridine produced a time-dependent increase in caspase activity that was prevented by Ca(2+) removal and TTX (10 microM). In addition, calpain and caspases inhibitors partially prevented veratridine-induced death. These results indicate that chromaffin cells share with neurons the molecular machinery involved in apoptotic death and might be considered a good model to study neuronal death during neurodegeneration.

Asunto(s)

Apoptosis , Células Cromafines/efectos de los fármacos , Superóxidos/metabolismo , Veratridina/farmacología , Animales , Calcio/metabolismo , Caspasas/metabolismo , Bovinos , Supervivencia Celular/efectos de los fármacos , Células Cromafines/citología , Células Cromafines/enzimología , Células Cromafines/metabolismo , Daño del ADN/efectos de los fármacos , Activación Enzimática , Técnicas In Vitro , Neuronas/efectos de los fármacos , Neuronas/metabolismo

RESUMEN

Although the genetic link between the epsilon4 allele of apolipoprotein E (apoE) and Alzheimer's disease is well established, the isoform-specific activity of apoE underlying this correlation remains unclear. To determine whether apoE influences the neurotoxic actions of beta-amyloid (Abeta), we examined the effect of native preparations of apoE3 and E4 on Abeta-induced toxicity in primary cultures of rat hippocampal pyramidal neurons. The source of apoE was conditioned medium from HEK-293 cells stably transfected with human apoE3 or E4 cDNA. ApoE4 (10 microg/ml) alone was toxic to the cultures, whereas apoE3 had no effect. ApoE3 treatment prevented the toxicity induced by 10 microM Abeta(1-40) or Abeta(25-35). The apoE3 protective effect appears to be specific to Abeta-induced toxicity, because apoE3 did not protect against the cytotoxicity produced by NMDA or staurosporine, nor did apoE3 affect the increase in intracellular calcium induced by either NMDA or KCl. ApoE3 had no effect on the toxicity produced by Abeta in the presence of receptor-associated protein, an inhibitor of apoE receptors, particularly the LDL-receptor-related protein. Interaction with apoE receptors may not mediate the toxic actions of apoE4, because receptor-associated protein did not affect apoE4-induced neurotoxicity. Consistent with our previous biochemical experiments, analysis of the culture medium revealed that SDS-stable apoE3:Abeta complex is present in greater abundance than apoE4:Abeta complex. Thus, the protection from Abeta-induced neurotoxicity afforded by apoE3 treatment may result from clearance of the peptide by apoE3:Abeta complex formation and uptake by apoE receptors.

Asunto(s)

Péptidos beta-Amiloides/toxicidad , Apolipoproteínas E/farmacología , Células Piramidales/citología , Animales , Apolipoproteína E3 , Apolipoproteína E4 , Muerte Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Medios de Cultivo Condicionados/farmacología , Hipocampo/citología , Humanos , Riñón/citología , Proteínas Musculares/farmacología , Fármacos Neuroprotectores/farmacología , Células Piramidales/química , Células Piramidales/efectos de los fármacos , Ratas , Receptores de LDL/fisiología